Pil Højgaard has a medical degree from the University of Copenhagen in 2008. Since then, she has been employed in different specialties of internal medicine, mainly rheumatology. She began her specialist training in rheumatology in 2012 and the same year she initiated a nationwide co-operation of rheumatic departments in Denmark to ensure that valid registrations on smoking habits were available for almost 1400 patients with psoriatic arthritis (PsA) in the Danish DANBIO registry. Subsequently she investigated the association between tobacco smoking and response to Tumour Necrosis Factor Alpha Inhibitors in PsA, which was presented at the EULAR conference in 2014 followed by a manuscript publication in Annals of the Rheumatic Diseases.
Pil has been involved in clinical and epidemiological research projects1-4 and journal clubs since she was a student. Furthermore, she has been teaching physiotherapist students in rheumatic diseases at the Metropolitan University College and has served as a clinical supervisor for medical students and young doctors. Pil has been employed as research fellow at the Parker Institute (MSU) since March 1st 2015 where she was enrolled as a PhD student at the Faculty of Health Sciences, University of Copenhagen. According to the “MSU vision” Pil will promote the principles and practice of evidence-based medicine through knowledge-translation research and educational offerings bridging rheumatology and dermatology, pulling together preeminent researchers and thought-leaders in PsA and psoriasis (PsO), as well as patient partners. The aim of her PhD project is to identify prognostic factors in PsA. Prognostic factor research aims to identify factors associated with subsequent clinical outcome in people with a particular disease or health condition. Pil Højgaards PhD study will be based on the recommendations provided by the The PROGnosis RESearch Strategy (PROGRESS) Partnership5-8 - investigating the association between clinical characteristics and pain profiles in different PsA populations and determine the prognostic value of for instance pain profiles on treatment outcome, using various research designs including prospective cohorts, national registries, and meta-epidemiology.
1) Højgaard P, Glintborg B, Hetland ML, et al: Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Ann Rheum Dis. 2014 Jul 25
2) Højgaard Christensen P, Barnung S, Steinmetz J. Mechanical cardiac massage Ugeskr Laeger. 2009 Aug 24;171(35):2463-5.
3): Eng GP, Bendtzen K, Bliddal H, Stoltenberg M, Szkudlarek M, Fana V, Lindegaard HM, Omerovic E, Højgaard P, Jensen EK, Bouchelouche PN. Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study. Arthritis. 2015;2015:784825
4) Glintborg B, Højgaard P, Hetland ML, et al: Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry. (Submitted)
5) Hemingway Harry, Croft Peter, Perel Pablo, Hayden Jill A, Abrams Keith, Timmis Adam et al. Prognosis research strategy (PROGRESS) 1: A framework for researching clinical outcomes BMJ 2013; 346:e5595
6) Riley RD, Hayden JA, Steyerberg EW, Moons KGM, Abrams K, et al. (2013) Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research. PLoS Med 10(2): e1001380. doi:10.1371/journal.pmed.1001380
7) Steyerberg EW, Moons KGM, van der Windt DA, Hayden JA, Perel P, et al. (2013) Prognosis Research Strategy (PROGRESS) 3: Prognostic Model Research. PLoS Med 10(2): e1001381. doi:10.1371/journal.pmed.1001381